Nuveen, LLC Protagonist Therapeutics, Inc Transaction History
Nuveen, LLC
- $315 Billion
- Q1 2025
A detailed history of Nuveen, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Nuveen, LLC holds 152,771 shares of PTGX stock, worth $6.76 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
152,771Holding current value
$6.76 Million% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PTGX
# of Institutions
263Shares Held
55.6MCall Options Held
226KPut Options Held
218K-
Farallon Capital Management LLC San Francisco, CA5.93MShares$263 Million1.22% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$255 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.5MShares$243 Million3.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.28MShares$189 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$147 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.17B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...